DV
Dividend Vision

MGRX — Mangoceuticals, Inc. Common Stock

Mangoceuticals, Inc. Common Stock (MGRX)

Total return is -99.1% over the past 3.4 years, 201.9 points behind SPY at 102.8%. Its deepest 1-year drawdown was 94.1%.

Mangoceuticals, Inc. develops and markets men's wellness products and services through a telemedicine platform, offering treatments for erectile dysfunction, hair loss, hormone balance, weight loss, and low testosterone under brands including Mango, Grow, Mojo, Slim, and Prime, with online fulfillment through licensed pharmacies. The company does not currently distribute dividends to shareholders. This security appeals to investors seeking exposure to the telehealth and men's health sectors, though it carries the risk profile typical of early-stage healthcare companies.

MGRX key facts

Asset type
Stock
Asset class
Equity
Inception date
03/21/2023
Last close
$0.53
Market cap
$8,085,855
Average volume
20904300.0
Beta
2.28
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.42